resources
Community
Health Advisors
Patient Education
Patient Education Booklets
Other Sources
Glossaries
FAQS
News
Electronic CMN
  Search Apria articles:
 
     
 Channels
Cancer
Caregivers
Degenerative Conditions
Diabetes
Heart
Infectious Diseases
Pediatrics
Respiratory
Seniors
Sleep Disorders
 
 
 
 
 
  Basis of lisinopril-binding specificity in human ACE reported
 
 

Scientists present the structural basis of the lisinopril-binding specificity in N- and C-domains of human somatic angiotensin I-converting enzyme (ACE)in a recent issue of Biochemical and Biophysical Research Communications.

According to recent research from Brazil, "Angiotensin I-converting enzyme (ACE) is a dipeptidyl carboxypeptidase which converts angiotensin I into the vasopressor peptide angiotensin II and also inactivates the hypotensive peptide bradykinin, playing an important role in blood pressure regulation. The present work describes the molecular modeling of the N-terminal human somatic ACE in complex with the inhibitor lisinopril, identifying the residues involved in the inhibitor-binding pocket."

"The obtained results identify differences in the lisinopril lysine moiety-binding residues for N- and C-terminals of sACE domains and an important carboxy-terminal proline hydrophobic accommodations mediated by the aromatic ring of Tyr-(532) and Tyr(1128) residues, respectively," reported Jorge H. Fernandez and colleagues at the Structural Bioinformatic Laboratory and the Instituto Butantan in Brazil. "The present model will be useful for the development of a new inhibitor family based on the natural BPP peptides and derivatives, or even to improve the binding capacities and the domain specificity of the already known inhibitors."

Fernandez and his coauthors published their study in Biochemical and Biophysical Research Communications (Structural basis of the lisinopril-binding specificity in N- and C-domains of human somatic ACE. Biochem Biophys Res Commun, 2003;308(2):219-226).

For additional information, contact Goran Neshich, Structural Bioinformatic Laboratory, CNPTIA-EMBRAPA, Campinas, SP, Brazil. E-mail: neshich@cbi.cnptia.embrapa.br.

Publisher contact information for the journal Biochemical and Biophysical Research Communications is: Academic Press Inc., Elsevier Science, 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA.

The information in this article comes under the major subject areas of Angiotensin, Angiology, Cardiology, Hypertension, and Proteomics. This article was prepared by Biotech Week editors from staff and other reports.

To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com.

 
  ©Copyright 2003, Biotech Week via NewsRx.com & NewsRx.net
 
 
 
Contact Us | Terms & Conditions | Privacy Policy | HIPAA Privacy Notice
 
2004 Apria Healthcare All Rights Reserved.
No duplication of any material herein is authorized without the express consent of Apria Healthcare, Inc.
Please review the Terms and Conditions of this Web site.